Pharmacy & Drug Pricing
Expert articles and analysis related to pharmacy & drug pricing.
AI Summary — Last 30 Days
CMS is moving drug-pricing policy deeper into Medicaid value-based purchasing: every state has applied for the GENEROUS Model, which would apply most-favored-nation pricing concepts to Medicaid drugs and create new rebate and access dynamics for state agencies, manufacturers, Medicaid MCOs, safety-net providers, and VBC organizations managing total cost of care (AHA). At the same time, CMS appears to be using cross-program
Related Articles
STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs
Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no price cuts in Medicare.
Three takeaways from Trump's latest drug pricing event
President Donald Trump announced voluntary drug pricing deals with nine new companies on Monday, for the first time veering outside of the original crop of companies that he singled out in letters las...
Mid-cap biotechs join Trump’s latest round of drug pricing deals
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies.
Midsized Biotechs Strike MFN Drug Pricing Deals
Trump strikes Medicaid drug price deals with pharma firms
Trump strikes Medicaid drug price deals with pharma firms Modern Healthcare
Trump announces nine new MFN drug pricing deals
Nine new companies have announced voluntary drug pricing deals with the White House, looking to avoid industry tariffs and inclusion in two CMS pilot programs under review that are thought to be poten...
Trump strikes nine more deals with drugmakers to lower prices
President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
Pharma's legal battle over Medicare negotiations reaches 'dead end'
The pharma industry has suffered a definitive loss in its legal battle against Medicare negotiations. The Fifth Circuit Court of Appeals on Wednesday rejected a challenge brought by the industry tra...
Brand Drugmakers Raised Prices on 250 Drugs this Summer
Brand Drugmakers Raised Prices on 250 Drugs this Summer AHIP
STAT+: 5 burning questions on Trump’s latest deals with drugmakers
Here are some of the key questions about the agreements the Trump administration has reached with drugmakers on pricing.